<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00420511</url>
  </required_header>
  <id_info>
    <org_study_id>065-00</org_study_id>
    <nct_id>NCT00420511</nct_id>
  </id_info>
  <brief_title>Beta-Cell Function and Sitagliptin Trial (BEST)</brief_title>
  <acronym>BEST</acronym>
  <official_title>A Randomized Controlled Pilot Study Assessing the Effect of Sitagliptin on the Preservation of Beta-Cell Function in Patients With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samuel Lunenfeld Research Institute, Mount Sinai Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Samuel Lunenfeld Research Institute, Mount Sinai Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by progressive
      deterioration in the function of the pancreatic beta-cells, which are the cells that produce
      and secrete insulin (the hormone primarily responsible for the handling of glucose in the
      body). The investigators propose a double-blind, randomized controlled pilot study comparing
      the effect of sitagliptin (a novel anti-diabetic drug with beta-cell protective potential)
      versus placebo, on the preservation of beta-cell function over one year in patients with T2DM
      on metformin, the first-line agent for the treatment of T2DM (ie. the study groups will be
      (i) sitagliptin and metformin versus (ii) placebo and metformin). This study may demonstrate
      an important beta-cell protective capacity of sitagliptin.

      Hypothesis: In patients with T2DM on metformin, treatment with the DPP-IV inhibitor
      sitagliptin will preserve pancreatic beta-cell function.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Medications currently used in the treatment of T2DM have not been shown to modify the
      progressive decline in beta-cell function that occurs over time. Recent evidence, however,
      suggests that a new class of anti-diabetic medications, called dipeptidyl peptidase-IV
      (DPP-IV) inhibitors, may be able to protect beta cells and hence alter the natural history of
      T2DM. We thus wish to study the effect of sitagliptin (a DPP-IV inhibitor) on the
      preservation of beta-cell function in patients with T2DM randomized to either (i) sitagliptin
      and metformin or (ii) placebo and metformin.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Preservation of Beta-cell Function Measured by Area-under-the-curve (C-peptide/Glucose)/HOMA-IR</measure>
    <time_frame>48 weeks</time_frame>
    <description>Area-under-the-C-peptide-curve (AUCCpep) and area-under-the-glucose-curve (AUCgluc) from 0 to 240 minutes during meal tests were calculated using the trapezoidal rule. Insulin resistance was assessed using the Homeostasis Model Assessment of Insulin Resistance (HOMA-IR). Beta-cell function was assessed using the ratio of total AUCCpep to AUCgluc divided by HOMA-IR (AUCCpep/gluc/HOMA-IR), a measure of insulin secretion in the context of ambient insulin sensitivity, analogous to the disposition index and adaptation index. Higher AUCCpep/gluc/HOMA-IR is indicative of better beta-cell function.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Insulinogenic Index Divided by HOMA-IR at 48 Weeks</measure>
    <time_frame>48 weeks</time_frame>
    <description>Insulinogenic index was calculated as the incremental change in insulin from 0 to 30 minutes divided by the incremental change in glucose over the same period of time. Insulinogenic index divided by HOMA-IR provides an additional measure of beta-cell function. A higher value indicates better beta-cell function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting Blood Glucose at 48 Weeks</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area-under-the-glucose-curve (AUCglucose) on Meal Test at 1 Year</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Loss of Glycemic Control</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients Achieving Sustained Normoglycemia Off Medication at 1-week Post-insulin Therapy</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Sitagliptin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sitagliptin 100mg once a day (od) by mouth (po)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo once a day (od) by mouth (po)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitagliptin</intervention_name>
    <description>sitagliptin 100 mg once a day</description>
    <arm_group_label>Sitagliptin</arm_group_label>
    <other_name>januvia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo once a day</description>
    <arm_group_label>Placebo arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>metformin</intervention_name>
    <description>metformin 1000 mg twice a day (bid) by mouth (po)</description>
    <arm_group_label>Sitagliptin</arm_group_label>
    <arm_group_label>Placebo arm</arm_group_label>
    <other_name>glucophage</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Men and women between the ages of 30 and 75 inclusive

          2. Physician-diagnosed type 2 diabetes on 0-2 oral hypoglycemic agents

          3. Negative for anti-glutamic acid decarboxylase (anti-GAD_ antibodies (to rule out
             Latent Autoimmune Diabetes of Adults (LADA)

          4. A1c at screening between 6.5% and 9% inclusive if on no oral hypoglycemic agents or
             6.0% and 9.0% inclusive if on 1-2 oral hypoglycemic agents

        Exclusion Criteria:

          1. Current insulin therapy

          2. Type 1 diabetes or secondary forms of diabetes

          3. Any major illness with a life expectancy of &lt; 5 years or that may interfere with the
             patient's participation in the study

          4. Involvement in any other study requiring drug therapy

          5. Renal dysfunction as evidenced by serum creatinine &gt;/= 136 umol/L for males or &gt;/= 124
             umol/L for females or abnormal creatinine clearance (&lt; 60 ml/min by Modification of
             Diet in Renal Disease (MDRD) formula)

          6. Hepatic disease considered to be clinically significant (includes jaundice, chronic
             hepatitis, or previous liver transplant) or transaminases &gt; 2.5 times the upper limit
             of normal

          7. Excessive alcohol consumption, defined as &gt; 14 alcoholic drinks per week for males and
             &gt; 9 alcoholic drinks per week for females

          8. Pregnancy or unwillingness to use reliable contraception. Women should not be planning
             pregnancy for the duration of the study. Reliable contraception includes: birth
             control pill, intra-uterine device, abstinence, tubal ligation, partner vasectomy, or
             condoms with spermicide. Any women who miss a menstrual period or think that they may
             be pregnant must have a pregnancy test as soon as possible

          9. History of serious arrhythmia or atrioventricular block on baseline electrocardiogram

         10. Uncontrolled hypertension (systolic blood pressure &gt; 180 mm Hg or diastolic blood
             pressure &gt; 110 mm Hg)

         11. Unwillingness to undergo multiple daily insulin injection therapy for 4 weeks

         12. Unwillingness to perform capillary blood glucose monitoring at least 4 times per day
             during intensive insulin therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bernard Zinman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Leadership Sinai Centre for Diabetes, University of Toronto</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ravi Retnakaran, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Leadership Sinai Centre for Diabetes, University of Toronto</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Leadership Sinai Centre for Diabetes</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 3L9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>December 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 10, 2007</study_first_submitted>
  <study_first_submitted_qc>January 10, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2007</study_first_posted>
  <results_first_submitted>June 24, 2011</results_first_submitted>
  <results_first_submitted_qc>December 20, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 29, 2011</results_first_posted>
  <last_update_submitted>December 28, 2011</last_update_submitted>
  <last_update_submitted_qc>December 28, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 2, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Samuel Lunenfeld Research Institute, Mount Sinai Hospital</investigator_affiliation>
    <investigator_full_name>Bernard Zinman</investigator_full_name>
    <investigator_title>Director, Leadership Sinai Centre for Diabetes</investigator_title>
  </responsible_party>
  <keyword>Type 2 diabetes</keyword>
  <keyword>beta-cell function</keyword>
  <keyword>sitagliptin</keyword>
  <keyword>intensive insulin therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Sitagliptin Phosphate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited from outpatient clinics at the Leadership Sinai Centre for Diabetes between February 2007 and October 2008.</recruitment_details>
      <pre_assignment_details>Participants underwent prerandomization phase of 4-8 weeks of intensive insulin therapy (IIT) consisting of basal detemir and premeal insulin aspart. Only participants who achieved fasting glucose &lt;7.0 mmol/L 1 day after completing IIT were randomized to either sitagliptin 100 mg once daily or matching placebo.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Sitagliptin</title>
          <description>Sitagliptin 100 mg once daily and metformin 1000 mg twice a day (bid) by mouth po</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Matching placebo once daily and metformin 1000 mg twice a day (bid) by mouth (po)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sitagliptin</title>
          <description>Sitagliptin 100 mg once daily and metformin 1000 mg twice a day (bid) by mouth po</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Matching placebo once daily and metformin 1000 mg twice a day (bid) by mouth (po)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="11"/>
            <count group_id="B3" value="21"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.3" lower_limit="45.5" upper_limit="69.5"/>
                    <measurement group_id="B2" value="60.8" lower_limit="51.3" upper_limit="61.4"/>
                    <measurement group_id="B3" value="60.9" lower_limit="47.9" upper_limit="61.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>kg/m^2</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34.3" lower_limit="27.3" upper_limit="42.6"/>
                    <measurement group_id="B2" value="32.7" lower_limit="31.0" upper_limit="41.1"/>
                    <measurement group_id="B3" value="32.7" lower_limit="28.6" upper_limit="41.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of diabetes</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.8" lower_limit="2.0" upper_limit="4.0"/>
                    <measurement group_id="B2" value="3.5" lower_limit="2.0" upper_limit="8.0"/>
                    <measurement group_id="B3" value="3.0" lower_limit="2.0" upper_limit="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HbA1c</title>
          <units>percent glycosylated hemoglobin</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.2" lower_limit="5.8" upper_limit="6.9"/>
                    <measurement group_id="B2" value="6.1" lower_limit="5.9" upper_limit="6.9"/>
                    <measurement group_id="B3" value="6.1" lower_limit="5.8" upper_limit="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Area-Under-The-Curve (C-peptide/glucose) / HOMA-IR</title>
          <description>Area-under-the-C-peptide-curve (AUCCpep) and area-under-the-glucose-curve (AUCgluc) from 0 to 240 minutes during meal tests were calculated by trapezoidal rule. Insulin resistance was assessed by Homeostasis Model Assessment of Insulin Resistance (HOMA-IR). Beta-cell function was assessed using the ratio of AUCCpep to AUCgluc divided by HOMA-IR (AUCCpep/gluc/HOMA-IR), a measure of insulin secretion in the context of ambient insulin sensitivity, analogous to the disposition index and Insulin Secretion-Sensitivity Index-2 (ISSI-2). Higher AUCCpep/gluc/HOMA-IR indicates better beta-cell function.</description>
          <units>index of beta-cell function</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="114.8" lower_limit="76.3" upper_limit="208.7"/>
                    <measurement group_id="B2" value="126.0" lower_limit="79.8" upper_limit="159.8"/>
                    <measurement group_id="B3" value="120.0" lower_limit="66.3" upper_limit="129.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Preservation of Beta-cell Function Measured by Area-under-the-curve (C-peptide/Glucose)/HOMA-IR</title>
        <description>Area-under-the-C-peptide-curve (AUCCpep) and area-under-the-glucose-curve (AUCgluc) from 0 to 240 minutes during meal tests were calculated using the trapezoidal rule. Insulin resistance was assessed using the Homeostasis Model Assessment of Insulin Resistance (HOMA-IR). Beta-cell function was assessed using the ratio of total AUCCpep to AUCgluc divided by HOMA-IR (AUCCpep/gluc/HOMA-IR), a measure of insulin secretion in the context of ambient insulin sensitivity, analogous to the disposition index and adaptation index. Higher AUCCpep/gluc/HOMA-IR is indicative of better beta-cell function.</description>
        <time_frame>48 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin</title>
            <description>Sitagliptin 100 mg once daily and metformin 1000 mg twice a day (orally administered)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo once daily and metformin 1000 mg twice a day (orally administered)</description>
          </group>
        </group_list>
        <measure>
          <title>Preservation of Beta-cell Function Measured by Area-under-the-curve (C-peptide/Glucose)/HOMA-IR</title>
          <description>Area-under-the-C-peptide-curve (AUCCpep) and area-under-the-glucose-curve (AUCgluc) from 0 to 240 minutes during meal tests were calculated using the trapezoidal rule. Insulin resistance was assessed using the Homeostasis Model Assessment of Insulin Resistance (HOMA-IR). Beta-cell function was assessed using the ratio of total AUCCpep to AUCgluc divided by HOMA-IR (AUCCpep/gluc/HOMA-IR), a measure of insulin secretion in the context of ambient insulin sensitivity, analogous to the disposition index and adaptation index. Higher AUCCpep/gluc/HOMA-IR is indicative of better beta-cell function.</description>
          <units>index of beta-cell function</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.4" lower_limit="52.5" upper_limit="205.6"/>
                    <measurement group_id="O2" value="71.2" lower_limit="40.3" upper_limit="139.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Insulinogenic Index Divided by HOMA-IR at 48 Weeks</title>
        <description>Insulinogenic index was calculated as the incremental change in insulin from 0 to 30 minutes divided by the incremental change in glucose over the same period of time. Insulinogenic index divided by HOMA-IR provides an additional measure of beta-cell function. A higher value indicates better beta-cell function</description>
        <time_frame>48 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin</title>
            <description>Sitagliptin 100 mg once daily and metformin 1000 mg twice a day (bid) by mouth po</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo once daily and metformin 1000 mg twice a day (bid) by mouth (po)</description>
          </group>
        </group_list>
        <measure>
          <title>Insulinogenic Index Divided by HOMA-IR at 48 Weeks</title>
          <description>Insulinogenic index was calculated as the incremental change in insulin from 0 to 30 minutes divided by the incremental change in glucose over the same period of time. Insulinogenic index divided by HOMA-IR provides an additional measure of beta-cell function. A higher value indicates better beta-cell function</description>
          <units>index of beta-cell function</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" lower_limit="1.9" upper_limit="4.9"/>
                    <measurement group_id="O2" value="1.8" lower_limit="1.3" upper_limit="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fasting Blood Glucose at 48 Weeks</title>
        <time_frame>48 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin</title>
            <description>Sitagliptin 100 mg once daily and metformin 1000 mg twice a day (bid) by mouth po</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo once daily and metformin 1000 mg twice a day (bid) by mouth (po)</description>
          </group>
        </group_list>
        <measure>
          <title>Fasting Blood Glucose at 48 Weeks</title>
          <units>mmol/l</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.9" lower_limit="5.5" upper_limit="7.4"/>
                    <measurement group_id="O2" value="6.7" lower_limit="6.0" upper_limit="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area-under-the-glucose-curve (AUCglucose) on Meal Test at 1 Year</title>
        <time_frame>1 year</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Loss of Glycemic Control</title>
        <time_frame>1 year</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients Achieving Sustained Normoglycemia Off Medication at 1-week Post-insulin Therapy</title>
        <time_frame>1 year</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Sitagliptin</title>
          <description>Sitagliptin 100 mg once daily and metformin 1000 mg twice a day (bid) by mouth po</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Matching placebo once daily and metformin 1000 mg twice a day (bid) by mouth (po)</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal tumor</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Generalized rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The modest sample size of this pilot study may have lacked sufficient statistical power to detect an effect on preservation of beta-cell function.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Ravi Retnakaran</name_or_title>
      <organization>Leadership Sinai Centre for Diabetes, Mount Sinai Hospital</organization>
      <phone>416-586-4800 ext 3941</phone>
      <email>rretnakaran@mtsinai.on.ca</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

